View from Brussels

Peter O'Donnell is a freelance journalist who specializes in European health affairs and is based in Brussels, Belgium.

Articles

The latest initiative against COVID, the European Health Emergency Preparedness and Response Authority, is taking shape with intentions of revealing the vulnerabilities in global supply chains and more.

Europe's Leaders Still Discussing How to Respond to the COVID Pandemic

After three years, member states of the EU have yet to make any real progress on legislation that would coordinate their clinical assessments more closely.

HTA—Easier to Reach Global Consensus Than an Agreement in Europe

Cancer still a primary focus of EMA in light of COVID and vaccine development.

EMA’s Cooke Reviews European Cancer Prospects

The $4 billion program will embrace the disease's entire pathway, from prevention to quality of life of patients and survivors.

Beating Cancer in Europe—And Beating Some of The Discrimination That Cancer Generates

After issuing a conditional marketing authorization issued just a week ago for the Moderna vaccine and receiving applications for more, the EU has reserved vaccines sufficient to treat more than 80% of the European population. 

Battling COVID on the Policy Front in Europe

As the EMA gives Moderna's COVID vaccine the thumbs up, the European Commission has quickly followed up with its own approval.

Three Kings Come Through with Another COVID Vaccine for Europe

Despite all the hopes and wishes for a better new year, the start to 2021 in Europe is proving to be grimly similar to the end of 2020.

Plus Ça Change…Nothing Changes With a New Year!

The EU has its first COVID vaccine authorized. 

EU Joins the COVID Vaccine Gang

Europe's leaders find themselves in a strange situation as their defense of their systematic approach to drug registration via the EMA has come under fire not only externally, but from some of their own politicians as well. 

COVID Vaccines' Collateral Damage to EU

As the UK's Medicines and Healthcare products Regulatory Agency gave approval to the Pfizer/BioNTech COVID vaccine—questions about how they had been so quick, or why the EU had been so slow, have risen.